Norwegian version of this page

Metabolomics and chemosensitivity

This project investigates the role of stromal cells in the development of chemoresistance in pancreatic cancer cells.

About the project

Despite treatment advances, PDAC has a dismal 5-year survival rate (<7%). The failure to translate the effects of existing therapeutics into better survival benefits for patient with pancreatic ductal adenocarcinoma (PDAC) is mainly linked to the development of treatment resistance.

The experiments are based on primary cultures of human PDAC-derived cancer cells and PSCs and tumor tissue biopsies. In this project, multiomics techniques including genomics, proteomics, metabolomics and lipidomics are employed.

Illustration made by: Manoj Amrutkar


  • Lars O. Dragsted, University of Copenhagen, Denmark
  • Jan Borén, University of Gothenburg, Sweden


  • University of Oslo
  • South-Eastern Norway Regional Health Authority (HSØ), project nr. 2020062

Study period

  • 2018 - ongoing
Published Apr. 4, 2019 12:42 PM - Last modified Apr. 19, 2021 4:24 PM